Edition:
United States

ArQule Inc (ARQL.OQ)

ARQL.OQ on NASDAQ Stock Exchange Global Market

1.13USD
10:39am EDT
Change (% chg)

$-0.02 (-1.74%)
Prev Close
$1.15
Open
$1.13
Day's High
$1.14
Day's Low
$1.11
Volume
10,014
Avg. Vol
20,571
52-wk High
$1.82
52-wk Low
$0.92

Chart for

About

ArQule, Inc. is a biopharmaceutical company. The Company is engaged in the research and development of therapeutics to treat cancers and rare diseases. These drugs focuses on the biological pathways implicated in a range of cancers and certain non-oncology indications. Its clinical-stage pipeline consists of over four drug... (more)

Overall

Beta: 1.51
Market Cap(Mil.): $81.85
Shares Outstanding(Mil.): 71.17
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 78.94 16.33
EPS (TTM): -- -- --
ROI: -- 2.84 14.66
ROE: -- 4.61 13.99

BRIEF-Arqule Inc CEO Paolo Pucci​ buys 19,156 shares of co's common stock on Sept 5

* Arqule Inc CEO Paolo Pucci​ reports purchase of 19,156 shares of co's common stock on Sept 5 at average price of $1.14 per share - SEC filing Source text: (http://bit.ly/2j4eXnk) Further company coverage:

Sep 06 2017

BRIEF-Arqule Q2 loss per share $0.10

* Q2 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

Aug 04 2017

BRIEF-Arqule Q1 loss per share $0.11

* Q1 earnings per share view $-0.11 -- Thomson Reuters I/B/E/S

May 03 2017

BRIEF-ArQule receives clearance of IND application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

* ArQule receives clearance of investigational new drug application from the FDA for proprietary reversible BTK inhibitor, ARQ 531

Apr 11 2017

BRIEF-Arqule trial did not meet its primary endpoint of progression free survival

* Trial did not meet its primary endpoint of progression free survival (pfs).

Mar 27 2017

Earnings vs. Estimates